113 related articles for article (PubMed ID: 35234441)
1. Bioengineered Protein Nanocage by Small Heat Shock Proteins Delivering mTERT siRNA for Enhanced Colorectal Cancer Suppression.
Wang H; Liu N; Yang F; Hu N; Wang M; Cui M; Bruns N; Guan X
ACS Appl Bio Mater; 2022 Mar; 5(3):1330-1340. PubMed ID: 35234441
[TBL] [Abstract][Full Text] [Related]
2. Engineered Hsp Protein Nanocages for siRNA Delivery.
Guan X; Chang Y; Sun J; Song J; Xie Y
Macromol Biosci; 2018 May; 18(5):e1800013. PubMed ID: 29665276
[TBL] [Abstract][Full Text] [Related]
3. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
4. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment targeting with dual stimuli-responsive nanoparticles based on small heat shock proteins for antitumor drug delivery.
Shi K; Wang Y; Zhou X; Gui H; Xu N; Wu S; He C; Zhao Z
Acta Biomater; 2020 Sep; 114():369-383. PubMed ID: 32688090
[TBL] [Abstract][Full Text] [Related]
6. Virus-mimetic polymeric micelles for targeted siRNA delivery.
Xiong XB; Uludağ H; Lavasanifar A
Biomaterials; 2010 Aug; 31(22):5886-93. PubMed ID: 20427082
[TBL] [Abstract][Full Text] [Related]
7. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene.
Tian Z; Wang H; Jia Z; Shi J; Tang J; Mao L; Liu H; Deng Y; He Y; Ruan Z; Li J; Wu Y; Ni B
Curr Cancer Drug Targets; 2010 Dec; 10(8):932-41. PubMed ID: 20879980
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional PEI-entrapped gold nanoparticles enable efficient delivery of therapeutic siRNA into glioblastoma cells.
Kong L; Qiu J; Sun W; Yang J; Shen M; Wang L; Shi X
Biomater Sci; 2017 Jan; 5(2):258-266. PubMed ID: 27921110
[TBL] [Abstract][Full Text] [Related]
10. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal escaped protein nanocarriers for nuclear-targeted siRNA delivery.
Cao X; Shang X; Guo Y; Zheng X; Li W; Wu D; Sun L; Mu S; Guo C
Anal Bioanal Chem; 2021 May; 413(13):3493-3499. PubMed ID: 33770206
[TBL] [Abstract][Full Text] [Related]
12. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo.
Xia Y; Tang G; Guo M; Xu T; Chen H; Lin Z; Li Y; Chen Y; Zhu B; Liu H; Cao J
Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110594. PubMed ID: 32204058
[TBL] [Abstract][Full Text] [Related]
13. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
14. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
15. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
16. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
Uchida T; Kanazawa T; Kawai M; Takashima Y; Okada H
J Pharmacol Exp Ther; 2011 Aug; 338(2):443-50. PubMed ID: 21531792
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers.
Bao H; Zheng N; Li Z; Zhi Y
Drug Des Devel Ther; 2020; 14():3057-3068. PubMed ID: 32801644
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.
Liu L; Liu X; Xu Q; Wu P; Zuo X; Zhang J; Deng H; Wu Z; Ji A
Int J Nanomedicine; 2014; 9():3509-26. PubMed ID: 25114522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
